- Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020 ...
Researchers at the Medical University of Vienna and the Medical University of Innsbruck discovered that SARS-CoV-2 hijacks three important host proteins that dampen the activity of the complement ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
This is a preview. Log in through your library . Abstract Rabbits sensitized by multiple injections of living BCG until their serums showed high concentrations of antibodies to tuberculoprotein and ...
The idea that old vaccines might have a role in the fight against COVID-19 has been floated since the early days of the pandemic. Vaccines stimulate the broad, innate immune response, which appears to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback